v3.26.3
Long-term Debt - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Oct. 31, 2026
Aug. 12, 2026
Sep. 30, 2026
Sep. 30, 2026
Nov. 18, 2025
Debt Instrument [Line Items]          
Unamortized deferred financing costs     $ 3,600,000 $ 3,600,000  
Unamortized original issue discount costs     10,400,000 10,400,000  
Amortization expense related to deferred financing costs and original issue discount.     $ 600,000 $ 1,800,000  
Zero Cost Interest Rate Collar Agreements One | Subsequent Event          
Debt Instrument [Line Items]          
Notional amount $ 375,000,000        
Zero Cost Interest Rate Collar Agreements Two | Subsequent Event          
Debt Instrument [Line Items]          
Notional amount $ 375,000,000        
SOFR | Subsequent Event          
Debt Instrument [Line Items]          
Interest rate added to base rate (as a percent) 5.25%        
Floor Rate | Debt Mature in February 2029 | Subsequent Event          
Debt Instrument [Line Items]          
Interest rate added to base rate (as a percent) 4.25%        
Floor Rate | Debt Mature in February 2030 | Subsequent Event          
Debt Instrument [Line Items]          
Interest rate added to base rate (as a percent) 4.30%        
Credit Agreement          
Debt Instrument [Line Items]          
Debt instrument remaining cash flows original terms percentage     10.00% 10.00%  
Credit agreement amendment, arranger fees and recognized       $ 2,600,000  
Write off deferred financing costs with extinguished portion of the debt       $ 500,000  
Credit Agreement | Senior Secured Term Loan A Facility          
Debt Instrument [Line Items]          
Debt instrument remaining cash flows amended terms percentage     10.00% 10.00%  
Credit Agreement | Senior Secured Term Loan B Facility          
Debt Instrument [Line Items]          
Debt instrument remaining cash flows amended terms percentage     10.00% 10.00%  
Credit Agreement | JPMorgan Chase Bank, N.A. | Senior Secured Term Loan A Facility | Avadel Pharmaceuticals Plc          
Debt Instrument [Line Items]          
Aggregate principal amount   $ 745,300,000      
Line of credit facility maturity date   Feb. 12, 2031      
Interest rate added to base rate (as a percent)       0.75%  
Credit Agreement | JPMorgan Chase Bank, N.A. | Senior Secured Term Loan B Facility | Avadel Pharmaceuticals Plc          
Debt Instrument [Line Items]          
Aggregate principal amount   $ 773,100,000      
Line of credit facility maturity date   Aug. 12, 2031      
Interest rate added to base rate (as a percent)       0.50%  
Credit Agreement | SOFR | JPMorgan Chase Bank, N.A. | Senior Secured Term Loan A Facility | Avadel Pharmaceuticals Plc          
Debt Instrument [Line Items]          
Interest rate added to base rate (as a percent)       2.25%  
Credit Agreement | Alternate Base Rate | JPMorgan Chase Bank, N.A. | Senior Secured Term Loan A Facility | Avadel Pharmaceuticals Plc          
Debt Instrument [Line Items]          
Interest rate added to base rate (as a percent)       1.25%  
Credit Agreement | Maximum | SOFR | Senior Secured Term Loan A Facility | Avadel Pharmaceuticals Plc          
Debt Instrument [Line Items]          
Interest rate added to base rate (as a percent)       2.25%  
Credit Agreement | Maximum | Alternate Base Rate | Senior Secured Term Loan A Facility | Avadel Pharmaceuticals Plc          
Debt Instrument [Line Items]          
Interest rate added to base rate (as a percent)       1.25%  
Credit Agreement | Minimum          
Debt Instrument [Line Items]          
Debt instrument remaining cash flows amended terms percentage     10.00% 10.00%  
Credit Agreement | Minimum | SOFR | Senior Secured Term Loan A Facility | Avadel Pharmaceuticals Plc          
Debt Instrument [Line Items]          
Interest rate added to base rate (as a percent)       1.75%  
Credit Agreement | Minimum | Alternate Base Rate | Senior Secured Term Loan A Facility | Avadel Pharmaceuticals Plc          
Debt Instrument [Line Items]          
Interest rate added to base rate (as a percent)       0.75%  
Bridge Term Loan Credit Agreement | JPMorgan Chase Bank, N.A. | Avadel Pharmaceuticals Plc          
Debt Instrument [Line Items]          
Aggregate principal amount         $ 1,500,000,000
Financing costs     $ 0 $ 7,400,000